Search Within

David H Ilson

  1. "Biostatistics Service"
Formats
  1. Journal Article (43)
  2. Meeting Abstract (42)
  3. Miscellaneous (1)
Groups
  1. Biostatistics Service (86)
  2. Department of Medicine (86)
  3. Epidemiology and Biostatistics (86)
  4. Gastrointestinal Oncology Service (86)
  5. Solid Tumor Oncology Division (86)
  6. Center for Pancreatic Cancer Research (82)

More Groups

People
  1. Marinela Capanu (65)
  2. Yelena Janjigian (60)
  3. Geoffrey Ku (56)
  4. David Kelsen (53)
  5. Joanne Chou (36)
  6. Laura Tang (28)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (10)
  4. 2022 (6)
  5. 2021 (6)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (45)
  2. Annals of Surgical Oncology (5)
  3. Annals of Surgery (4)
  4. Cancer (4)
  5. Clinical Cancer Research (3)
  6. JAMA Network Open (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (45)
  2. Springer (9)
  3. American Association for Cancer Research (6)
  4. Lippincott Williams & Wilkins (5)
  5. Oxford University Press (5)
  6. Wiley Blackwell (4)

More Publishers

Results (86)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer
    Meeting Abstract

    Janjigian, Y. Y.; Ku, G. Y.; Ilson, D. H.; Boyar, M. S.; Capanu, M.; Chou, J. F.; Kelsen, D. P.; Imtiaz, T.; Berger, M. F.; Vakiani, E.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Activity of genacitabine/5-FU combination in refractory esophagogastrie (EG) cancer
    Meeting Abstract

    Won, E.; Ilson, D. H.; Chou, J. F.; Capanu, M.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer
    Meeting Abstract

    Janjigian, Y. Y.; Capanu, M.; Imtiaz, T.; Kelsen, D. P.; Ku, G. Y.; Schattner, M.; Brown, K. T.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Activity of gemcitabine/5-FU combination in refractory esophagogastric (EG) cancer
    Meeting Abstract

    Won, E.; Ilson, D. H.; Chou, J. F.; Capanu, M.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • FDG-PET scan after induction chemotherapy for esophageal squamous cell cancer (ESCC) to predict for outcomes after chemoradiation (chemoRT) and to guide salvage chemotherapy during RT
    Meeting Abstract

    Ku, G. Y.; Janjigian, Y. Y.; Kriplani, A.; Ong, L.; Rusch, V. W.; Bains, M. S.; Rizk, N. P.; Sarkaria, I. S.; Capanu, M.; Goodman, K. A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Evaluation of PET response to neoadjuvant therapy for patients with gastric and GEJ adenocarcinoma
    Meeting Abstract

    Hernandez, J.; Beylergil, V.; Goldman, D.; Tang, L. H.; Ilson, D. H.; Downey, R.; Strong, V. E.; Shah, M.; Gonen, M.; Schoder, H.; more...
    Annals of Surgical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer
    Journal Article

    Janjigian, Y. Y.; Ku, G. Y.; Campbell, J. C.; Shah, M. A.; Capanu, M.; Kelsen, D. P.; Ilson, D. H.
    American Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma
    Journal Article

    Gerber, N.; Ilson, D. H.; Wu, A. J.; Janjigian, Y. Y.; Kelsen, D. P.; Zheng, J.; Zhang, Z.; Bains, M. S.; Rizk, N.; Rusch, V. W.; more...
    Diseases of the Esophagus (2014)

    Fulltext@MSK | Save
  • Phase II study of preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in patients with locally advanced gastric and GEJ adenocarcinoma
    Meeting Abstract

    Won, E.; Ilson, D.; Kelsen, D. P.; Strong, V. E.; Schoder, H.; Janjigian, Y. Y.; Shah, M. A.; Coit, D. G.; Brennan, M. F.; Capanu, M.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Janjigian, Y. Y.; Shah, M. A.; Herrera, J.; Tang, L. H.; Fuqua, L.; Capanu, M.; Ilson, D.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save